kabutan

Eisai Co., Ltd.(4523) Summary

4523
TSE Prime
Eisai Co., Ltd.
4,636
JPY
-73
(-1.55%)
Dec 5, 2:23 pm JST
29.95
USD
Dec 5, 12:23 am EST
Result
PTS
outside of trading hours
4,640.8
Dec 5, 2:21 pm JST
Summary Chart Historical News Financial Result
PER
31.5
PBR
1.53
Yield
3.45%
Margin Trading Ratio
19.70
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
4,660 JPY 30.03 USD
Previous Close Dec 4
4,709 JPY 30.30 USD
High Dec 5, 9:01 am
4,686 JPY 30.21 USD
Low Dec 5, 9:18 am
4,634 JPY 29.86 USD
Volume
453,300
Trading Value
2.11B JPY 0.01B USD
VWAP
4654.44 JPY 30.07 USD
Minimum Trading Value
463,600 JPY 2,995 USD
Market Cap
1.35T JPY 8.78B USD
Number of Trades
1,782
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
3,776
1-Year High May 15, 2025
11,589
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 90,400 1,624,900 17.97
Nov 21, 2025 66,400 1,682,200 25.33
Nov 14, 2025 70,100 1,717,600 24.50
Nov 7, 2025 73,300 1,793,300 24.47
Oct 31, 2025 81,100 1,715,000 21.15
Company Profile
Eisai Co., Ltd. is a major pharmaceutical company with strengths in neurology and gastrointestinal oncology. The company has expanded into the field of dementia treatments.
Sector
Pharmaceuticals
Eisai's pharmaceutical business accounts for 90% of its sales, encompassing research and development, manufacturing, and sales of both prescription and over-the-counter medicines. The company has a strong global presence with a high overseas sales ratio. Outside Japan, Eisai operates in North America, China, EMEA (Europe, Middle East, Africa, Russia, and Oceania), and Asia-Latin America (South Korea, Taiwan, India, ASEAN, and Latin America). Internationally, Eisai conducts business through its subsidiaries in various regions. In Japan, the company collaborates with group companies such as KAN Research Institute and EA Pharma to advance its operations. In the United States, Eisai markets an Alzheimer's disease treatment that gained attention as the world's first medication to demonstrate a reduction in early clinical symptom progression during clinical trials. Leveraging its global research and development infrastructure and sales network, Eisai aims to provide pharmaceuticals that meet the needs of patients worldwide.